| Next 10 |
Ad
VYGR News and Press Voyager Therapeutics Inc.
News | Voyager Therapeutics Inc. (NASDAQ:VYGR)
-
2024-11-29 11:20:25 ET More on Voyager Therapeutics Voyager Therapeutics' Tracer Platform Targets CNS Market: Here's Why I'm Neutral Voyager Therapeutics, Inc. (VYGR) Q3 2024 Earnings Call Transcript Voyager selects gene therapy development candidate for Alzheimer&#x...
-
2024-11-25 13:30:00 ET Summary Investing in biotech offers high upside but comes with significant risks, especially with volatile stock movements and binary outcomes from clinical trials, says Jonathan Faison. Focus on multi-year clinical and commercial momentum, diversifying with...
-
2024-11-20 08:37:46 ET More on Voyager Therapeutics Voyager Therapeutics' Tracer Platform Targets CNS Market: Here's Why I'm Neutral Voyager Therapeutics, Inc. (VYGR) Q3 2024 Earnings Call Transcript Voyager: Anti-Tau Antibody Differentiation For AD Treatment Could B...
-
- Candidate VY1706 demonstrates significant reductions of tau at low doses in NHP study; IND and CTA filings anticipated in 2026 - - VY1706 is the fifth neuro gene therapy development candidate nominated leveraging Voyager’s IV-delivered, CNS-penetrant TRACER capsids - LE...
-
2024-11-18 11:37:23 ET Summary Voyager Therapeutics leverages its TRACER platform for targeted gene therapies, focusing on challenging CNS diseases like Alzheimer’s and ALS. Its pipeline includes a promising Phase 1 anti-tau Alzheimer’s therapy, VY7523, with data exp...
-
2024-11-12 23:07:47 ET Voyager Therapeutics, Inc. (VYGR) Q3 2024 Results Earnings Conference Call November 12, 2024, 04:30 PM ET Company Participants Trista Morrison - Chief Corporate Affairs Officer and Chief of Staff to the CEO Alfred Sandrock - President and Chief...
-
2024-11-12 16:05:17 ET More on Voyager Therapeutics Voyager: Anti-Tau Antibody Differentiation For AD Treatment Could Boost Prospects Voyager Therapeutics: CNS Player In Early Stages Of A Turnaround Voyager Therapeutics Q3 2024 Earnings Preview Novartis licen...
-
- Enrollment and dosing complete in single ascending dose clinical trial of anti-tau antibody VY7523 for Alzheimer’s; on track to generate top-line data H1 2025 - - Recent third-party clinical data establish that an antibody can inhibit tau accumulation in the human brain; provide ...
-
LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report third quarter 2024 financial and operating results after market close on Tuesday, November...
-
LEXINGTON, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the joint steering committee with its collaborator Neurocrine Biosciences, Inc. has selected a development ca...
Stock Information
Get VYGR Alerts
News, Short Squeeze, Breakout and More Instantly...
Voyager Therapeutics Inc. Company Name:
VYGR Stock Symbol:
NASDAQ Market:
Voyager Therapeutics Inc. Website:
Ad
-
- Candidate VY1706 demonstrates significant reductions of tau at low doses in NHP study; IND and CTA filings anticipated in 2026 - - VY1706 is the fifth neuro gene therapy development candidate nominated leveraging Voyager’s IV-delivered, CNS-penetrant TRACER capsids - LE...
-
- Enrollment and dosing complete in single ascending dose clinical trial of anti-tau antibody VY7523 for Alzheimer’s; on track to generate top-line data H1 2025 - - Recent third-party clinical data establish that an antibody can inhibit tau accumulation in the human brain; provide ...
-
LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report third quarter 2024 financial and operating results after market close on Tuesday, November...